Cidara Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Cidara Therapeutics
CDTX Stock  USD 22.75  0.48  2.16%   
Cidara Therapeutics financial statements provide useful quarterly and yearly information to potential Cidara Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cidara Therapeutics financial statements helps investors assess Cidara Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cidara Therapeutics' valuation are summarized below:
Gross Profit
-70.6 M
Market Capitalization
243.9 M
Enterprise Value Revenue
47.1333
Revenue
1.3 M
Earnings Share
(26.82)
We have found one hundred twenty available fundamental signals for Cidara Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Cidara Therapeutics prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 131.1 M in 2025. Enterprise Value is likely to rise to about (14.8 M) in 2025

Cidara Therapeutics Total Revenue

1.21 Million

Check Cidara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cidara Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 210.4 K, Selling General Administrative of 14.7 M or Other Operating Expenses of 186.2 M, as well as many indicators such as Price To Sales Ratio of 141, Dividend Yield of 0.0 or PTB Ratio of 1.1. Cidara financial statements analysis is a perfect complement when working with Cidara Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cidara Therapeutics Correlation against competitors.
For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.

Cidara Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets225.5 M214.8 M72.5 M
Slightly volatile
Short and Long Term Debt Total5.2 M3.6 M5.9 M
Pretty Stable
Other Current Liabilities9.3 M18.3 M6.9 M
Slightly volatile
Total Current Liabilities27.5 M49.6 M20.5 M
Slightly volatile
Accounts Payable2.7 M3.6 M2 M
Slightly volatile
Cash199.3 M189.8 M62.6 M
Slightly volatile
Non Current Assets Total2.8 M4.1 M2.1 M
Slightly volatile
Non Currrent Assets Other91.2 K96 K491.6 K
Slightly volatile
Other Assets905.3 K1.2 M733.5 K
Slightly volatile
Cash And Short Term Investments199.3 M189.8 M62.6 M
Slightly volatile
Common Stock Shares Outstanding6.7 M6.3 M1.9 M
Slightly volatile
Liabilities And Stockholders Equity225.5 M214.8 M72.5 M
Slightly volatile
Non Current Liabilities Total1.8 M1.9 M5.8 M
Slightly volatile
Other Current Assets20.2 M19.2 M5.3 M
Slightly volatile
Other Stockholder Equity813.3 M774.6 M263.1 M
Slightly volatile
Total Liabilities34.9 M51.5 M26.3 M
Slightly volatile
Total Current Assets221.3 M210.7 M70.3 M
Slightly volatile
Other Liabilities22.2 M21.2 M8.8 M
Slightly volatile
Property Plant And Equipment Net2.2 M4 M1.7 M
Slightly volatile
Property Plant And Equipment Gross7.7 M7.3 M2.6 M
Slightly volatile
Common Stock95010002.8 K
Slightly volatile
Property Plant Equipment189.8 K199.8 K829.8 K
Slightly volatile
Common Stock Total Equity8.5 K8.1 K3.6 K
Slightly volatile
Capital Surpluse293.1 M464.7 M261.1 M
Slightly volatile
Non Current Liabilities Other24.8 M23.6 M7.7 M
Slightly volatile
Net Receivables1.6 M1.7 M3.1 M
Slightly volatile
Long Term Debt Total6.8 M6.5 M8.3 M
Slightly volatile
Short and Long Term Debt2.2 M2.3 M6.9 M
Slightly volatile
Short Term Debt1.6 M1.6 M7 M
Slightly volatile
Current Deferred Revenue15.4 M28.9 M11.4 M
Slightly volatile
Capital Stock95010003.7 K
Pretty Stable
Capital Lease Obligations2.7 M3.6 M2.1 M
Slightly volatile

Cidara Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative14.7 M20.6 M11 M
Slightly volatile
Other Operating Expenses186.2 M177.4 M62.4 M
Slightly volatile
Research Development51.5 M71.9 M38.5 M
Slightly volatile
Total Operating Expenses66.2 M92.5 M49.5 M
Slightly volatile
Non Recurring1.3 M1.4 M1.6 M
Slightly volatile
Preferred Stock And Other Adjustments2.4 M2.5 M7 M
Slightly volatile
Interest Income6.1 M5.8 M1.3 M
Slightly volatile

Cidara Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.9 M3.9 M2.9 M
Slightly volatile
Begin Period Cash Flow49.5 M35.8 M36.9 M
Slightly volatile
Other Non Cash Items3.2 M3.1 M674.6 K
Slightly volatile
End Period Cash Flow206 M196.2 M58.9 M
Slightly volatile
Change To Netincome3.9 M4.1 M3.3 M
Slightly volatile
Issuance Of Capital Stock354.2 M337.3 M55.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio14113421.2203
Slightly volatile
Days Sales Outstanding50948593.7036
Slightly volatile
Stock Based Compensation To Revenue3.223.06430.577
Slightly volatile
Payables Turnover24.723.52635.6213
Slightly volatile
Sales General And Administrative To Revenue16.9816.16862.6989
Slightly volatile
Research And Ddevelopement To Revenue59.1956.37579.1943
Slightly volatile
Capex To Revenue0.110.10120.0159
Slightly volatile
Cash Per Share28.429.895479.8483
Pretty Stable
Days Payables Outstanding14.7415.51451.7 K
Slightly volatile
Income Quality0.661.03950.8083
Pretty Stable
Current Ratio5.214.25274.1748
Very volatile
Receivables Turnover0.720.75271.3 K
Slightly volatile
Capex Per Share0.01930.02037.7457
Slightly volatile
Average Receivables11 M9 M10.9 M
Slightly volatile
Revenue Per Share0.190.200812.3669
Slightly volatile
Interest Debt Per Share0.540.563226.0519
Slightly volatile
Debt To Assets0.01580.01661.9087
Slightly volatile
Days Of Payables Outstanding14.7415.51451.7 K
Slightly volatile
Ebt Per Ebit1.110.9671.0561
Slightly volatile
Long Term Debt To Capitalization0.01280.01354.3933
Slightly volatile
Quick Ratio5.234.25274.1883
Very volatile
Net Income Per E B T0.810.99730.9768
Pretty Stable
Cash Ratio4.963.83073.9762
Very volatile
Days Of Sales Outstanding50948593.7036
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.00071.0538
Slightly volatile
Fixed Asset Turnover0.310.321711.8183
Very volatile
Debt Ratio0.01580.01661.9087
Slightly volatile
Price Sales Ratio14113421.2203
Slightly volatile
Asset Turnover0.00560.00590.3879
Pretty Stable

Cidara Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap131.1 M170.7 M140.1 M
Slightly volatile

Cidara Fundamental Market Drivers

Forward Price Earnings5.7504
Cash And Short Term Investments189.8 M

Cidara Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cidara Therapeutics Financial Statements

Cidara Therapeutics investors use historical fundamental indicators, such as Cidara Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cidara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue28.9 M15.4 M
Total Revenue1.3 M1.2 M
Cost Of Revenue84.9 M89.1 M
Stock Based Compensation To Revenue 3.06  3.22 
Sales General And Administrative To Revenue 16.17  16.98 
Research And Ddevelopement To Revenue 56.38  59.19 
Capex To Revenue 0.10  0.11 
Revenue Per Share 0.20  0.19 
Ebit Per Revenue(138.12)(131.21)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY